drugset
Drugs / hCD19.IL15.CAR-iNKT
last change Apr 2024 re-read 3 minutes ago

hCD19.IL15.CAR-iNKT

also known as hCD19.IL15.CAR-iNKT cells
Developed for
chronic lymphocytic leukemia/small lymphocytic lymphoma
Investigated by
Affiliated Hospital of Jiangsu University · First Affiliated Hospital of Zhejiang University · Huai'an First People's Hospital · Kai Lin Xu; Jun Nian Zheng · Nantong University · North Jiangsu People's Hospital
+1 more · The First People's Hospital of Changzhou

Trials 1

today NCT04814004 · Ph 1
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04814004 Mar 2021 → Apr 2023 chronic lymphocytic leukemia/small lymphocytic lymphoma Kai Lin Xu; Jun Nian Zheng Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as hCD19.IL15.CAR-iNKT ClinicalTrials.gov intervention name — accepted as the source's own label NCT04814004 ↗
Known as hCD19.IL15.CAR-iNKT cells “This study aims to evaluate the safety and feasibility of hCD19.IL15.CAR-iNKT cells in treating patients with relapsed/refractory/high-risk B-cell tumors.” NCT04814004 ↗
Route Intravenous “Universal hCD19.IL15.CAR-iNKT cells by a single infusion intravenously will be given in escalating doses.” NCT04814004 ↗